Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVL006 and 9MW2821 in Advanced Solid Tumors
NCT07615660Phase 2Not yet recruiting
- Sponsor
- Convalife Pharmaceutical
- Start
- May 2026
- Primary completion
- Apr 2029
01
Overview
Phase 2, randomised, open-label trial of CVL006 in solid tumor (3 arms), sponsored by Convalife Pharmaceutical. Primary endpoint: Progression-Free Survival at 36 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
CVL006
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07615660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07615660.